Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: A clinicopathologic study of 281 cases

Cancer

Volumn 103, Issue 9, 2005, Pages 1881-1890

  Sato, Osamu ^a   Wada, Takuro ^a   Kawai, Akira ^b   Yamaguchi, Umio ^b   Makimoto, Atsushi ^b   Kokai, Yasuo ^a   Yamashita, Toshihiko ^a   Chuman, Hirokazu ^b   Beppu, Yasuo ^b   Tani, Yoichi ^c   Hasegawa, Tadashi ^d  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c DakoCytomation Co Ltd   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Adult; EHBB2; Epidermal growth factor receptor (EGFR); KIT; Soft tissue sarcoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; STEM CELL FACTOR; TYROSINE KINASE RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; FIBROSARCOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MULTIMODALITY CANCER THERAPY; NERVE SHEATH TUMOR; PRIORITY JOURNAL; SCHOOL CHILD; SOFT TISSUE SARCOMA; SPINDLE CELL SARCOMA; SYNOVIAL SARCOMA;

ADULT; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SARCOMA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 20244389571     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20986     Document Type: Article

References (46)

1. Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 1997;24:556-560.
2. Stojadinovic A, Leung DH, Allen P, Lewis JJ, Jaques DP, Brennan MF. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol. 2002;20:4344-4352.
3. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986:319:226-230.
4. Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell. 1989;58:287-292.
5. Wada T, Qian XL, Greene MI. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell. 1990;61:1339-1347.
6. Wada T, Myers JN, Kokai Y, Brown VI, Hamuro J, LeVea CM, et al. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins. Oncogene. 1990;5:489-495.
7. Potti A, Willardson J, Forseen C, Kishor Ganti A, Koch M, Hebert B, et al. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer. 2002;36:257-261.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
9. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
10. Dugan MC, Dergham ST, Kucway R, Singh K, Biernat L, Du W, et al. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas. 1997;14:229-236.
11. Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH, et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol. 2001;14:1277-1283.
12. Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94:1397-1404.
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med. 2001;344:783-792.
14. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
15. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003;95:851-867.
16. Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood. 1992;80:374-381.
17. DiPaola RS, Kuczynski WI, Onodera K, Ratajczak MZ, Hijiya N, Moore J, et al. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther. 1997;4:176-182.
18. Tian Q, Frierson HF, Jr., Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol. 1999;154:1643-1647.
19. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
20. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
21. Hasegawa T, Yamamoto S, Yokoyama R, Umeda T, Matsuno Y, Hirohashi S. Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer. 2002;95:843-851.
22. Fletcher CD, Sundaram M, Rydholm A, Coindre JM, Singer S. Soft tissue tumours: epidemiology, clinical features, histological typing and grading. In: Fletcher CD, Unni KK, Mertens F. World Health Organization classification of tumours, pathology and genitics: tumors of soft tissue and bone. Lyon: IARCPress, 2002:12-18.
23. Hasegawa T, Yokoyama R, Lee YH, Shimoda T, Beppu Y, Hirohashi S. Prognostic relevance of a histological grading system using MIB-1 for adult soft-tissue sarcoma. Oncology. 2000;58:66-74.
24. Hasegawa T, Yamamoto S, Nojima T, Hirose T, Nikaido T, Yamashiro K, et al. Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas. Hum Pathol. 2002;33:111-115.
25. Spaulding DC, Spaulding BO. Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol. 2002;29:45-54.
26. Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK. Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci USA. 2003;100:9330-9335.
27. Gusterson B, Cowley G, McIlhinney J, Ozanne B, Fisher C, Reeves B. Evidence for increased epidermal growth factor receptors in human sarcomas. Int J Cancer. 1985;36:689-693.
28. Perosio PM, Brooks JJ. Expression of growth factors and growth factor receptors in soft tissue tumors. Implications for the autocrine hypothesis. Lab Invest. 1989;60:245-253.
29. Duda RB, Cundiff D, August CZ, Wagman LD, Bauer KD. Growth factor receptor and related oncogene determination in mesenchymal tumors. Cancer. 1993;71:3526-3530.
30. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 2002;359:1301-1307.
31. Barbashina V, Benevenia J, Aviv H, Tsai J, Patterson F, Aisner S, et al. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases. J Cancer Res Clin Oncol 2002;128:610-616.
32. Nielsen TO, Hsu FD, O'Connell JX, Gilks CB, Sorensen PH, Linn S, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol. 2003;163:1449-1456.
33. Sato T, Peiper M, Heinecke A, Zurakowski D, Eisenberger CF, Hosch S, et al. Expression of HER-2/neu Does not Correlate with Survival in Soft Tissue Sarcoma. Onkologie. 2003;26:268-271.
34. Foster H, Knox S, Ganti AK, Hebert BJ, Koch M, Tendulkar K, et al. HER-2/neu overexpression detected by immunohistochemistry in soft tissue sarcomas. Am J Clin Oncol. 2003;26:188-191.
35. Merimsky O, Issakov J, Schwartz I, Dadia S, Kollender Y, Bickels J, et al. Lack of ErbB-2 oncogene product overexpression in soft tissue sarcomas. Acta Oncol. 2002;41:366-368.
36. Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol. 2002;26:486-492.
37. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol. 2002;117:188-193.
38. Bolen JW, Thorning D. Liposarcomas. A histogenetic approach to the classification of adipose tissue neoplasms. Am J Surg Pathol. 1984;8:3-17.
39. Chorneyko K. The ultrastructure of liposarcomas with attention to "dedifferentiation." Ultrastruct Pathol. 1997;21:545-557.
40. Hasegawa T, Seki K, Hasegawa F, Matsuno Y, Shimodo T, Hirose T, et al. Dedifferentiated liposarcoma of retroperitoneum and mesentery: varied growth patterns and histological grades: a clinicopathologic study of 32 cases. Hum Pathol. 2000;31:717-727.
41. Allander SV, Illei PB, Chen Y, Antonescu CR, Bittner M, Ladanyi M, et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol. 2002;161:1587-1595.
42. Nuciforo PG, Pellegrini C, Fasani R, Maggioni M, Coggi G, Parafioriti A, et al. Molecular and immunohistochemical analysis of HER-2/neu oncogene in synovial sarcoma. Hum Pathol. 2003;34:639-645.
43. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998;338:153-160.
44. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135-140.
45. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 2000;6:2166-2174.
46. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1:1311-1318.